Compare WRLD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | ESPR |
|---|---|---|
| Founded | 1962 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 828.1M | 814.3M |
| IPO Year | 1994 | 2013 |
| Metric | WRLD | ESPR |
|---|---|---|
| Price | $201.84 | $3.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 107.0K | ★ 9.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ 6.88 | N/A |
| Revenue | ★ $585,166,700.00 | $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | $12.81 |
| P/E Ratio | $28.31 | ★ N/A |
| Revenue Growth | 3.60 | ★ 21.31 |
| 52 Week Low | $110.00 | $0.95 |
| 52 Week High | $195.07 | $4.18 |
| Indicator | WRLD | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 82.95 | 67.43 |
| Support Level | $165.03 | $3.11 |
| Resistance Level | N/A | $3.18 |
| Average True Range (ATR) | 7.56 | 0.02 |
| MACD | 2.12 | -0.02 |
| Stochastic Oscillator | 97.80 | 62.50 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.